A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT00619099 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: decitabine
DRUG: decitabine

Sponsor

Eisai Inc.